 Karen Christopher
Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 11 | 2023 | 185 | 5.550 |
Why?
| | Cataract Extraction | 7 | 2023 | 76 | 4.400 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 42 | 3.060 |
Why?
| | Myopia | 4 | 2022 | 36 | 2.860 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2022 | 16 | 2.190 |
Why?
| | Phacoemulsification | 5 | 2023 | 107 | 2.160 |
Why?
| | Refraction, Ocular | 4 | 2022 | 30 | 1.790 |
Why?
| | Visual Acuity | 6 | 2023 | 274 | 1.650 |
Why?
| | Lasers, Excimer | 3 | 2022 | 21 | 1.600 |
Why?
| | Retinal Detachment | 2 | 2023 | 53 | 1.560 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 1.550 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 149 | 1.450 |
Why?
| | Blood Loss, Surgical | 2 | 2020 | 84 | 1.180 |
Why?
| | Ophthalmology | 2 | 2023 | 77 | 0.980 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.920 |
Why?
| | Optics and Photonics | 2 | 2021 | 41 | 0.890 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2022 | 6 | 0.840 |
Why?
| | Endothelium, Corneal | 1 | 2022 | 15 | 0.840 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 13 | 0.820 |
Why?
| | Retinal Perforations | 1 | 2022 | 12 | 0.790 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 57 | 0.750 |
Why?
| | Lens Subluxation | 1 | 2021 | 3 | 0.740 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 5 | 0.740 |
Why?
| | Corneal Stroma | 1 | 2020 | 15 | 0.720 |
Why?
| | Corneal Neovascularization | 1 | 2020 | 12 | 0.720 |
Why?
| | Keratitis | 1 | 2020 | 11 | 0.720 |
Why?
| | Endophthalmitis | 1 | 2020 | 25 | 0.710 |
Why?
| | Eye Infections, Bacterial | 1 | 2020 | 26 | 0.700 |
Why?
| | Hepatitis C | 1 | 2022 | 219 | 0.680 |
Why?
| | Vitreous Body | 1 | 2020 | 101 | 0.670 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2094 | 0.650 |
Why?
| | Heroin Dependence | 1 | 2019 | 22 | 0.640 |
Why?
| | Scurvy | 1 | 2019 | 12 | 0.640 |
Why?
| | Retrospective Studies | 13 | 2023 | 12542 | 0.600 |
Why?
| | Conjunctival Neoplasms | 1 | 2017 | 7 | 0.570 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 11 | 0.570 |
Why?
| | Fingolimod Hydrochloride | 1 | 2017 | 29 | 0.560 |
Why?
| | Conjunctiva | 1 | 2017 | 51 | 0.550 |
Why?
| | Intraoperative Complications | 3 | 2022 | 122 | 0.540 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 69 | 0.530 |
Why?
| | Anterior Chamber | 1 | 2015 | 19 | 0.510 |
Why?
| | Bacteria | 1 | 2020 | 725 | 0.460 |
Why?
| | Internship and Residency | 1 | 2023 | 926 | 0.450 |
Why?
| | Cytoprotection | 1 | 2013 | 51 | 0.450 |
Why?
| | Thrombocytopenia | 1 | 2015 | 177 | 0.440 |
Why?
| | alpha-Crystallin B Chain | 1 | 2013 | 18 | 0.440 |
Why?
| | Crystallins | 1 | 2013 | 39 | 0.430 |
Why?
| | Humans | 29 | 2023 | 114623 | 0.410 |
Why?
| | Lens, Crystalline | 1 | 2013 | 90 | 0.410 |
Why?
| | Hot Temperature | 1 | 2013 | 302 | 0.390 |
Why?
| | Postoperative Complications | 5 | 2023 | 2128 | 0.390 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 29 | 0.380 |
Why?
| | Cornea | 2 | 2022 | 102 | 0.370 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4411 | 0.350 |
Why?
| | Aged, 80 and over | 7 | 2023 | 6344 | 0.350 |
Why?
| | Academic Medical Centers | 2 | 2022 | 410 | 0.310 |
Why?
| | Oxidative Stress | 1 | 2013 | 1076 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3244 | 0.280 |
Why?
| | Male | 13 | 2023 | 55554 | 0.240 |
Why?
| | Capsule Opacification | 2 | 2021 | 20 | 0.240 |
Why?
| | Language | 2 | 2023 | 262 | 0.220 |
Why?
| | Ophthalmologists | 1 | 2023 | 12 | 0.220 |
Why?
| | Descemet Membrane | 1 | 2022 | 5 | 0.210 |
Why?
| | Wet Macular Degeneration | 1 | 2023 | 32 | 0.210 |
Why?
| | Geographic Atrophy | 1 | 2023 | 49 | 0.210 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 79 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 214 | 0.200 |
Why?
| | Aged | 8 | 2023 | 19061 | 0.200 |
Why?
| | Tissue and Organ Harvesting | 1 | 2022 | 62 | 0.200 |
Why?
| | Cell Count | 1 | 2022 | 303 | 0.200 |
Why?
| | Alanine Transaminase | 1 | 2022 | 141 | 0.200 |
Why?
| | Artificial Intelligence | 1 | 2023 | 144 | 0.200 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Microscopy | 1 | 2022 | 125 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.190 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.180 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.180 |
Why?
| | Political Activism | 1 | 2021 | 10 | 0.180 |
Why?
| | Dementia | 1 | 2023 | 187 | 0.180 |
Why?
| | Intraoperative Period | 1 | 2020 | 51 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2023 | 200 | 0.180 |
Why?
| | Hepacivirus | 1 | 2022 | 229 | 0.180 |
Why?
| | Biometry | 1 | 2021 | 62 | 0.180 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.180 |
Why?
| | Eye Injuries | 1 | 2021 | 44 | 0.180 |
Why?
| | Tissue Donors | 1 | 2022 | 316 | 0.180 |
Why?
| | United States | 5 | 2023 | 12176 | 0.180 |
Why?
| | Vitrectomy | 1 | 2020 | 57 | 0.170 |
Why?
| | Laser Therapy | 1 | 2021 | 100 | 0.170 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.170 |
Why?
| | Tattooing | 1 | 2020 | 11 | 0.170 |
Why?
| | Female | 10 | 2023 | 59466 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2020 | 76 | 0.170 |
Why?
| | Middle Aged | 7 | 2023 | 26719 | 0.170 |
Why?
| | HIV | 1 | 2020 | 208 | 0.170 |
Why?
| | Macular Edema | 1 | 2020 | 34 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 368 | 0.160 |
Why?
| | Arthritis, Reactive | 1 | 2019 | 8 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | Uveitis | 1 | 2020 | 115 | 0.160 |
Why?
| | Prosthesis Design | 1 | 2020 | 285 | 0.150 |
Why?
| | Metformin | 1 | 2021 | 276 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2023 | 479 | 0.140 |
Why?
| | Biopsy | 2 | 2020 | 1036 | 0.140 |
Why?
| | Curriculum | 1 | 2023 | 819 | 0.140 |
Why?
| | Ultrasonography | 1 | 2020 | 633 | 0.140 |
Why?
| | Clinical Competence | 1 | 2023 | 893 | 0.140 |
Why?
| | Adult | 6 | 2020 | 30528 | 0.130 |
Why?
| | Case-Control Studies | 1 | 2022 | 3003 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1342 | 0.120 |
Why?
| | Cell-Penetrating Peptides | 1 | 2013 | 12 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 24 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2023 | 9084 | 0.110 |
Why?
| | Protein Structure, Quaternary | 1 | 2013 | 115 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 646 | 0.110 |
Why?
| | Cell Death | 1 | 2013 | 322 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1477 | 0.090 |
Why?
| | Cell Survival | 1 | 2013 | 1020 | 0.090 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1230 | 0.090 |
Why?
| | Risk Factors | 1 | 2022 | 8628 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 498 | 0.080 |
Why?
| | Cell Line | 1 | 2013 | 2635 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 1987 | 129 | 0.070 |
Why?
| | Intubation, Intratracheal | 1 | 1987 | 216 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2008 | 209 | 0.060 |
Why?
| | Safety-net Providers | 1 | 2023 | 95 | 0.050 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.050 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.050 |
Why?
| | Intravitreal Injections | 1 | 2020 | 45 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 22 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 44 | 0.040 |
Why?
| | Software | 1 | 2023 | 529 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 478 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 144 | 0.040 |
Why?
| | Health Surveys | 1 | 2021 | 443 | 0.040 |
Why?
| | Mutation | 1 | 2008 | 3344 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1008 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4099 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4405 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 6112 | 0.020 |
Why?
| | TRPP Cation Channels | 1 | 2008 | 63 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 167 | 0.020 |
Why?
| | Rest | 1 | 1987 | 103 | 0.020 |
Why?
| | Physical Exertion | 1 | 1987 | 209 | 0.020 |
Why?
| | Genetic Testing | 1 | 2008 | 379 | 0.020 |
Why?
| | Hypoxia | 1 | 1987 | 957 | 0.010 |
Why?
| | Young Adult | 1 | 2008 | 10455 | 0.010 |
Why?
|
|
Christopher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|